Arcus Biosciences (NYSE:RCUS) Reaches New 12-Month Low – Should You Sell?

Arcus Biosciences, Inc. (NYSE:RCUS)’s stock price reached a new 52-week low during trading on Wednesday . The stock traded as low as $12.83 and last traded at $13.00, with a volume of 305748 shares trading hands. The stock had previously closed at $13.09.

Analyst Upgrades and Downgrades

RCUS has been the subject of several analyst reports. HC Wainwright reiterated a “neutral” rating and issued a $20.00 price objective on shares of Arcus Biosciences in a research note on Wednesday, November 6th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Arcus Biosciences in a research note on Thursday, October 3rd. Wedbush reiterated an “outperform” rating and issued a $36.00 price objective on shares of Arcus Biosciences in a research note on Thursday, November 7th. Barclays increased their price objective on shares of Arcus Biosciences from $25.00 to $29.00 and gave the company an “overweight” rating in a research note on Friday, October 25th. Finally, Wells Fargo & Company assumed coverage on shares of Arcus Biosciences in a research note on Tuesday, October 8th. They issued an “overweight” rating and a $29.00 price objective for the company. One equities research analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, Arcus Biosciences has a consensus rating of “Buy” and a consensus target price of $32.67.

Arcus Biosciences Stock Performance

The company’s 50 day moving average price is $15.20 and its 200-day moving average price is $15.86. The company has a market cap of $1.19 billion, a PE ratio of -4.11 and a beta of 0.87. The company has a debt-to-equity ratio of 0.08, a quick ratio of 5.24 and a current ratio of 5.24.

Arcus Biosciences (NYSE:RCUS) last released its quarterly earnings data on Wednesday, November 6th. The company reported ($1.00) EPS for the quarter, topping the consensus estimate of ($1.06) by $0.06. The company had revenue of $48.00 million during the quarter, compared to the consensus estimate of $38.95 million. Arcus Biosciences had a negative net margin of 102.66% and a negative return on equity of 45.59%. Arcus Biosciences’s revenue for the quarter was up 50.0% on a year-over-year basis. During the same period last year, the firm earned ($0.94) EPS. Equities research analysts anticipate that Arcus Biosciences, Inc. will post -3.2 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Arcus Biosciences news, CFO Robert C. Goeltz II sold 3,594 shares of the firm’s stock in a transaction on Tuesday, December 31st. The shares were sold at an average price of $15.00, for a total value of $53,910.00. Following the completion of the transaction, the chief financial officer now directly owns 60,138 shares of the company’s stock, valued at $902,070. This trade represents a 5.64 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 12.30% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of RCUS. R Squared Ltd bought a new position in Arcus Biosciences in the 4th quarter valued at $26,000. Point72 Hong Kong Ltd bought a new stake in shares of Arcus Biosciences during the 3rd quarter worth $47,000. Point72 DIFC Ltd bought a new stake in shares of Arcus Biosciences during the 2nd quarter worth $83,000. Quest Partners LLC lifted its holdings in shares of Arcus Biosciences by 40,904.3% during the 3rd quarter. Quest Partners LLC now owns 9,431 shares of the company’s stock worth $144,000 after acquiring an additional 9,408 shares during the last quarter. Finally, Intech Investment Management LLC bought a new stake in shares of Arcus Biosciences during the 3rd quarter worth $244,000. 92.89% of the stock is owned by institutional investors.

Arcus Biosciences Company Profile

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.